Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dal-OUTCOMES 2 study of dalcetrapib in stable coronary heart disease or high cardiovascular risk
NL-OMON37839Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and coronary arteriosclerosis comparing Dalcetrapib plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Time to first major ischemic cardiovascular event. Planned start Mar 2012; status: not yet recruiting.
02
Drugs
dalcetrapib
03
Conditions
cardiac morbiditycoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON37839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37839.